These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22855758)

  • 1. Evidence for stopping mass drug administration for lymphatic filariasis in some, but not all local government areas of Plateau and Nasarawa States, Nigeria.
    King JD; Eigege A; Umaru J; Jip N; Miri E; Jiya J; Alphonsus KM; Sambo Y; Graves P; Richards F
    Am J Trop Med Hyg; 2012 Aug; 87(2):272-80. PubMed ID: 22855758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria.
    Richards FO; Eigege A; Miri ES; Kal A; Umaru J; Pam D; Rakers LJ; Sambo Y; Danboyi J; Ibrahim B; Adelamo SE; Ogah G; Goshit D; Oyenekan OK; Mathieu E; Withers PC; Saka YA; Jiya J; Hopkins DR
    PLoS Negl Trop Dis; 2011 Oct; 5(10):e1346. PubMed ID: 22022627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria.
    Eigege A; Evans DS; Noland GS; Davies E; Umaru J; Adelamo SE; Mancha B; King JD; Miri ES; Okoeguale B; Griswold EP; Richards FO
    Am J Trop Med Hyg; 2017 Sep; 97(3):677-680. PubMed ID: 28749759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of Onchocerciasis transmission after more than a decade of mass drug administration for onchocerciasis and lymphatic filariasis elimination in central Nigeria: challenges in coordinating the stop MDA decision.
    Evans DS; Alphonsus K; Umaru J; Eigege A; Miri E; Mafuyai H; Gonzales-Peralta C; Adamani W; Pede E; Umbugadu C; Saka Y; Okoeguale B; Richards FO
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3113. PubMed ID: 25233351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lymphatic filariasis transmission assessment survey in schools three years after stopping mass drug treatment with albendazole and ivermectin in the 7 endemic districts in Togo].
    Dorkenoo AM; Sodahlon YK; Bronzan RN; Yakpa K; Sossou E; Ouro-Medeli A; Teko M; Seim A; Mathieu E
    Bull Soc Pathol Exot; 2015 Aug; 108(3):181-7. PubMed ID: 25476256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is mass drug administration against lymphatic filariasis required in urban settings? The experience in Kano, Nigeria.
    Pam DD; de Souza DK; D'Souza S; Opoku M; Sanda S; Nazaradden I; Anagbogu IN; Okoronkwo C; Davies E; Elhassan E; Molyneux DH; Bockarie MJ; Koudou BG
    PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006004. PubMed ID: 29020042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of two tests for filarial antigenemia in areas in Sri Lanka and Indonesia with low-level persistence of lymphatic filariasis following mass drug administration.
    Yahathugoda TC; Supali T; Rao RU; Djuardi Y; Stefani D; Pical F; Fischer PU; Lloyd MM; Premaratne PH; Weerasooriya MV; Weil GJ
    Parasit Vectors; 2015 Jul; 8():369. PubMed ID: 26168919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of epidemiology of lymphatic filariasis in Nigeria.
    Waje T; Iliyasu C; Yaki LM; Auta IK
    Pan Afr Med J; 2024; 47():142. PubMed ID: 38933431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of mass drug administration and long-lasting insecticidal net distribution on Wuchereria bancrofti infection in humans and mosquitoes: an observational study in northern Uganda.
    Ashton RA; Kyabayinze DJ; Opio T; Auma A; Edwards T; Matwale G; Onapa A; Brooker S; Kolaczinski JH
    Parasit Vectors; 2011 Jul; 4():134. PubMed ID: 21756371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study.
    Fimbo AM; Mnkugwe RH; Mlugu EM; Kunambi PP; Malishee A; Minzi OMS; Kamuhabwa AAR; Aklillu E
    Infect Dis Poverty; 2024 Jun; 13(1):44. PubMed ID: 38867265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First evidence of lymphatic filariasis transmission interruption in Cameroon: Progress towards elimination.
    Nana-Djeunga HC; Tchouakui M; Njitchouang GR; Tchatchueng-Mbougua JB; Nwane P; Domche A; Bopda J; Mbickmen-Tchana S; Akame J; Tarini A; Epée E; Biholong BD; Zhang Y; Tougoue JJ; Kabore A; Njiokou F; Kamgno J
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005633. PubMed ID: 28662054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Treatment Surveillance for Lymphatic Filariasis in Plateau and Nasarawa States, Nigeria: Results of Transmission Assessment Surveys.
    Eigege A; Noland GS; Adelamo SE; Nwodu K; Sallau A; Umaru J; Mancha BS; Davies E; Danboyi J; Kadimbo JA; Saka YA; Anagbogu I; Miri ES; Richards FO
    Am J Trop Med Hyg; 2020 Jun; 102(6):1404-1410. PubMed ID: 32228796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated transmission assessment surveys (iTAS) of lymphatic filariasis and onchocerciasis in Cross River, Taraba and Yobe States, Nigeria.
    Anagbogu IN; Saka YA; Surakat OA; Okoronkwo C; Davies E; Oyale P; Ekpo UF; Amazigo UV; Barbre K; Igbe M; Nyior A; Jacob SM; Gideon Nteun U; Abubakar Umar Z
    Parasit Vectors; 2022 Jun; 15(1):201. PubMed ID: 35698164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets.
    Jones C; Ngasalla B; Derua YA; Tarimo D; Malecela MN
    Int J Infect Dis; 2017 Aug; 61():38-43. PubMed ID: 28527817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria.
    Griswold E; Eigege A; Ityonzughul C; Emukah E; Miri ES; Anagbogu I; Saka YA; Kadiri S; Adelamo S; Ugbadamu P; Ikogho C; Richards FO
    Am J Trop Med Hyg; 2018 Aug; 99(2):396-403. PubMed ID: 29943709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka.
    Rao RU; Samarasekera SD; Nagodavithana KC; Punchihewa MW; Ranasinghe USB; Weil GJ
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007365. PubMed ID: 31009482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of Wb123 antibody elisa in individuals treated with ivermectin and albendazole, and implementation challenges in Africa.
    de Souza DK; Owusu IO; Otchere J; Adimazoya M; Frempong K; Ahorlu CS; Boakye DA; Wilson MD
    Pan Afr Med J; 2017; 27():65. PubMed ID: 28819487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
    Pion SDS; Chesnais CB; Weil GJ; Fischer PU; Missamou F; Boussinesq M
    Lancet Infect Dis; 2017 Jul; 17(7):763-769. PubMed ID: 28372977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.
    Wamae CN; Njenga SM; Ngugi BM; Mbui J; Njaanake HK
    Acta Trop; 2011 Sep; 120 Suppl 1():S33-8. PubMed ID: 20933491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India.
    Subramanian S; Jambulingam P; Krishnamoorthy K; Sivagnaname N; Sadanandane C; Vasuki V; Palaniswamy C; Vijayakumar B; Srividya A; Raju HKK
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007862. PubMed ID: 31978060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.